Novartis says biosimilar rituximab accepted for review by FDA
ZURICH: Novartis AG said on Tuesday its biosimilar rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis were accepted for review by the U.S. Food and Drug Administration (FDA).
Rituximab, made by Novartis’ unit Sandoz, has been proposed as a biosimilar to Roche’s reference medicine Rituxan, Novartis said in a statement.
Rituximab was approved in Europe in June, Novartis said.
(Reporting by Silke Koltrowitz)
biosimilarblood cancersFDAimmunological diseasesNovartisrheumatoid arthritisRituxanRituximabSandozU.S. Food and Drug Administration
Source : REUTERSNext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd